Author:
Salvadores Natalia,Moreno-Gonzalez Inés,Ruiz Nazaret Gamez,Quiroz Gabriel,Vegas Laura,Escandón Marcela,Jimenez Sebastian,Vitorica Javier,Gutierrez Antonia,Soto Claudio,Court Felipe A.
Abstract
AbstractAlzheimer’s disease (AD) is a major adult-onset neurodegenerative condition with no available treatment. Compelling reports point amyloid-β (Aβ) as the main etiologic agent that triggers AD. Although there is extensive evidence of a detrimental crosstalk between Aβ and microglia that contributes to neuroinflammation in AD, the exact mechanism leading to neuron death remains unknown. Using postmortem human AD brain tissue, we show that Aβ oligomers (Aβo) colocalize with the necroptosis effector pMLKL. Moreover, we found that the burden of Aβo correlates with the expression of key markers of necroptosis activation. Additionally, inhibition of necroptosis by pharmacological or genetic means, reduce neurodegeneration and memory impairment triggered by Aβo in mice. Since microglial activation is emerging as a central driver for AD pathogenesis, we then tested the contribution of microglia to the mechanism of Aβo-mediated necroptosis activation in neurons. Using an in vitro model, we show that conditioned medium from Aβo-stimulated microglia elicited necroptosis in neurons through activation of TNF-α signaling, triggering extensive neurodegeneration. Notably, necroptosis inhibition provided significant neuronal protection. Together, these findings suggest that Aβo-mediated microglia stimulation in AD contributes to necroptosis activation in neurons and neurodegeneration. As necroptosis is a druggable degenerative mechanism, our findings might have important therapeutic implications to prevent the progression of AD.
Publisher
Cold Spring Harbor Laboratory
Reference77 articles.
1. Alzheimer’s Association, 2020 Alzheimer’s disease facts and figures;Alzheimer’s and Dementia,2020
2. The amyloid hypothesis of Alzheimer’s disease at 25 years;EMBO Molecular Medicine,2016
3. The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade;Journal of Alzheimer’s Disease,2018
4. Non-canonical soluble amyloid-beta aggregates and plaque buffering: Controversies and future directions for target discovery in Alzheimer’s disease;Alzheimer’s Research and Therapy,2017
5. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献